前列腺癌分子改变研究进展及中西方差异  

Progress in research and application of molecular changes in prostate cancer in China and the West

作　　者：张吉鲤 王子威 张文辉 汪涛 李晶 高旭 Zhang Jili;Wang Ziwei;Zhang Wenhui;Wang Tao;Li Jing;Gao Xu(Department of Urology,First Affiliated Hospital of Naval Medical University,Shanghai 200433,China)

机构地区：[1]海军军医大学第一附属医院泌尿外科,200433

出　　处：《中华泌尿外科杂志》2021年第3期233-236,共4页Chinese Journal of Urology

基　　金：国家自然科学基金(82022055);上海市青年科技启明星计划(20QA1411800)。

摘　　要：近年来,随着测序技术的发展和对不同人种前列腺癌分子改变的研究,前列腺癌发病机制呈现出明显的人种差异。本文综述前列腺癌中ETS融合基因及FOXA1、SPOP、IDH1基因突变等驱动基因的研究进展,并发现前列腺癌分子分型的研究呈现出中西方人群不同的分子改变。西方人群前列腺癌分子改变以ETS融合基因为主,而中国人群则以基因突变为主,主要为FOXA1突变和SPOP突变,且中国人群前列腺癌优势融合基因并非ETS融合基因,而是SCHLAP1-UBE2E3融合基因。In recent years,with the development of sequencing technology and research on molecular changes in different races of prostate cancer,it has been found that the pathogenesis of prostate cancer showed obvious ethnic differences.This article reviewed the research progress of ETS fusion genes,FOXA1,SPOP,IDH1 and other driver genes in prostate cancer.And the research of molecular typing of prostate cancer showed different patterns of molecular changes in Chinese and western populations.The molecular changes of prostate cancer in western populations were dominated by ETS fusion gene,while those in Chinese populations were dominated by gene mutations,mainly FOXA1 and SPOP mutations.Moreover,the dominant fusion gene in Chinese prostate cancer was not ETS fusion gene,but SCHLAP1-UBE2E3.

关 键 词：前列腺肿瘤 融合基因 突变 分子改变 精准治疗 

分 类 号：R737.25[医药卫生—肿瘤]